Medison Ventures

Medison Ventures is the corporate venture arm of Medison Pharma, a global pharmaceutical company focused on providing access to highly innovative therapies to patients in international markets. Leveraging over two decades of clinical and commercial expertise, Medison Ventures identifies and executes opportunities that add value to both Medison and its partners. The firm immerses itself in the healthcare ecosystem by engaging with academia, medical centers, patients, global pharma partners, and key opinion leaders. This comprehensive approach enables Medison Ventures to evaluate breakthrough technologies across various development stages and assess industry adoption readiness. The firm's investment strategy encompasses a wide range of stages, from seed to pre-IPO, and spans multiple geographical regions, including Israel, the United States, Europe, and parts of Asia and Africa. Medison Ventures focuses on sectors such as biotechnology, digital health, pharmaceuticals, medical devices, and healthcare IT. By acting as 'external R&D' for its global partners, the firm continuously researches and evaluates opportunities tailored to meet specific partner needs, driving pipeline growth and supporting long-term visions. Medison Ventures has made notable investments in companies such as Alpha Tau Medical, Orchard Therapeutics, and Allogene Therapeutics, focusing on sectors like biotechnology and drug discovery. Through its strategic alliances and investment vehicles, Medison Ventures seeks highly innovative products at advanced development stages for in-licensing and commercialization within Medison's covered territories. By acting as 'external R&D' for its global partners, the firm continuously researches and evaluates opportunities tailored to meet specific partner needs, driving pipeline growth and supporting long-term visions.

Innovative healthcare solutions, Advanced development stages, Potential for global commercialization, Alignment with Medison's strategic interests